Healthcare Industry News: neuromodulation
News Release - September 14, 2015
Incoming St. Jude Medical President and CEO Mike Rousseau Announces Executive Leadership TeamLeadership structure leverages strength of St. Jude Medical executive management team
ST. PAUL, Minn.--(Healthcare Sales & Marketing Network)--St. Jude Medical, Inc. (STJ) today announced the new executive leadership team that incoming President and Chief Executive Officer (CEO) Michael T. Rousseau has chosen to lead the organization into the next phase of growth and innovation. Effective Jan. 1, 2016, the new team alignment leverages the Company’s deep bench of talent and ensures the continuity of key leadership positions within St. Jude Medical.
“We are fortunate to have an executive team that’s uniquely qualified to continue St. Jude Medical’s growth story,” Rousseau said. “This is a remarkable team with a diverse set of experiences and a proven track record that will allow us to continue to transform and diversify the way we develop medical technologies in order to improve the care for patients around the world. Over the past several years, our executive team has made significant contributions to the business and shares in the excitement of the future of St. Jude Medical.”
The executive leadership team will include a new structure intended to drive organizational effectiveness and maximize the depth of experience of St. Jude Medical leaders. No changes, other than one addition, will be made to the current roster of St. Jude Medical Executive Officers. The following officers will report to Rousseau, effective Jan. 1, 2016:
- Paul Bae will continue to serve as Vice President, Human Resources and Chief Compliance Officer.
- Phil Ebeling will become Vice President, Chief Technology Officer, assuming responsibility for the global research and development and regulatory functions. In this capacity, Ebeling will become an Executive Officer of St. Jude Medical.
- Rachel Ellingson will become Vice President, Corporate Strategy, continuing oversight of global communications and expanding her responsibilities to include business development and merger and acquisition (M&A) integration.
- Eric Fain, Group President, will continue to have oversight of the Company’s clinical function and will assume responsibility for the global sales and marketing organizations. Aligning the Company’s clinical organization with global sales and marketing under Fain’s leadership will expand next-generation market development opportunities for St. Jude Medical – ensuring global cross-functional collaboration in these areas with a focus on reimbursement, market access, policy and clinical trial integration. Executive leaders directly responsible for global sales, marketing, market development and clinical programs will report to Fain.
- Scott Thome will continue to serve as Vice President, Global Operations.
- Jason Zellers will continue to serve as Vice President, General Counsel, but will also assume executive responsibility for the Company’s quality organization.
- Don Zurbay will continue to serve as Vice President, Chief Financial Officer, but will also assume executive responsibility for investor relations as well as the Company’s information technology function.
St. Jude Medical is a global medical device manufacturer dedicated to transforming the treatment of some of the world’s most expensive epidemic diseases. The company does this by developing cost-effective medical technologies that save and improve lives of patients around the world. Headquartered in St. Paul, Minn., St. Jude Medical has four major clinical focus areas that include cardiac rhythm management, atrial fibrillation, cardiovascular and neuromodulation. For more information, please visit sjm.com or follow us on Twitter @StJudeMedicalIR.
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. Such forward-looking statements include the expectations, plans and prospects for the Company, including potential clinical successes, anticipated regulatory approvals and future product launches, and projected revenues, margins, earnings and market shares. The statements made by the Company are based upon management’s current expectations and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include market conditions and other factors beyond the Company’s control and the risk factors and other cautionary statements described in the Company’s filings with the SEC, including those described in the Risk Factors and Cautionary Statements sections of the Company’s Annual Report on Form 10-K for the fiscal year ended January 3, 2015 and Quarterly Report on Form 10-Q for the fiscal quarter ended July 4, 2015. The Company does not intend to update these statements and undertakes no duty to any person to provide any such update under any circumstance.
Source: St. Jude Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.